Memorandum of Understanding Between the Food and Drug Administration and the University System of Maryland, 51449-51458 [07-4404]

Download as PDF Federal Register / Vol. 72, No. 173 / Friday, September 7, 2007 / Notices detailed description of the record contents they are seeking. DEPARTMENT OF HEALTH AND HUMAN SERVICES CONTESTING RECORD PROCEDURE: Food and Drug Administration Contact the official at the address specified under System Manager above, and identify the record and specify the information to be contested and corrective action sought with supporting justification to show how the record is inaccurate, incomplete, untimely, or irrelevant. Information is obtained from departments, agencies, or instrumentalities of the United States or any State and from multistate financial institutions and insurers (or their agents). ITEMS EXEMPTED FROM CERTAIN PROVISIONS OF THE ACT: None. [FR Doc. E7–17642 Filed 9–6–07; 8:45 am] mstockstill on PROD1PC66 with NOTICES BILLING CODE 4184–01–P 18:34 Sep 06, 2007 Memorandum of Understanding Between the Food and Drug Administration and the University System of Maryland AGENCY: Food and Drug Administration, HHS. RECORD SOURCE CATEGORIES: VerDate Aug<31>2005 [FDA 225–07–8405] Jkt 211001 ACTION: SUMMARY: The Food and Drug Administration (FDA) is providing notice of a memorandum of understanding (MOU) between FDA and the University System of Maryland to establish terms of collaboration to support shared interests that can proceed through a variety of programs including collaborative research, public outreach, cooperative international initiatives, interdisciplinary training, PO 00000 Frm 00046 Fmt 4703 and exchange of scientists and staff through sabbaticals, postdoctoral fellowships, and student internships. The agreement became effective July 12, 2007. DATES: FOR FURTHER INFORMATION CONTACT: Mary I. Poos, Office of External Relations (HF–10), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–2825. In accordance with 21 CFR 20.108(c), which states that all written agreements and MOUs between FDA and others shall be published in the Federal Register, the agency is publishing notice of this MOU. SUPPLEMENTARY INFORMATION: Notice. Sfmt 4703 51449 Dated: August 29, 2007. Jeffrey Shuren, Assistant Commissioner for Policy. BILLING CODE 4160–01–S E:\FR\FM\07SEN1.SGM 07SEN1 VerDate Aug<31>2005 Federal Register / Vol. 72, No. 173 / Friday, September 7, 2007 / Notices 18:34 Sep 06, 2007 Jkt 211001 PO 00000 Frm 00047 Fmt 4703 Sfmt 4725 E:\FR\FM\07SEN1.SGM 07SEN1 EN07SE07.038</GPH> mstockstill on PROD1PC66 with NOTICES 51450 VerDate Aug<31>2005 18:34 Sep 06, 2007 Jkt 211001 PO 00000 Frm 00048 Fmt 4703 Sfmt 4725 E:\FR\FM\07SEN1.SGM 07SEN1 51451 EN07SE07.039</GPH> mstockstill on PROD1PC66 with NOTICES Federal Register / Vol. 72, No. 173 / Friday, September 7, 2007 / Notices VerDate Aug<31>2005 Federal Register / Vol. 72, No. 173 / Friday, September 7, 2007 / Notices 18:34 Sep 06, 2007 Jkt 211001 PO 00000 Frm 00049 Fmt 4703 Sfmt 4725 E:\FR\FM\07SEN1.SGM 07SEN1 EN07SE07.040</GPH> mstockstill on PROD1PC66 with NOTICES 51452 VerDate Aug<31>2005 18:34 Sep 06, 2007 Jkt 211001 PO 00000 Frm 00050 Fmt 4703 Sfmt 4725 E:\FR\FM\07SEN1.SGM 07SEN1 51453 EN07SE07.041</GPH> mstockstill on PROD1PC66 with NOTICES Federal Register / Vol. 72, No. 173 / Friday, September 7, 2007 / Notices VerDate Aug<31>2005 Federal Register / Vol. 72, No. 173 / Friday, September 7, 2007 / Notices 18:34 Sep 06, 2007 Jkt 211001 PO 00000 Frm 00051 Fmt 4703 Sfmt 4725 E:\FR\FM\07SEN1.SGM 07SEN1 EN07SE07.042</GPH> mstockstill on PROD1PC66 with NOTICES 51454 VerDate Aug<31>2005 18:34 Sep 06, 2007 Jkt 211001 PO 00000 Frm 00052 Fmt 4703 Sfmt 4725 E:\FR\FM\07SEN1.SGM 07SEN1 51455 EN07SE07.043</GPH> mstockstill on PROD1PC66 with NOTICES Federal Register / Vol. 72, No. 173 / Friday, September 7, 2007 / Notices VerDate Aug<31>2005 Federal Register / Vol. 72, No. 173 / Friday, September 7, 2007 / Notices 18:34 Sep 06, 2007 Jkt 211001 PO 00000 Frm 00053 Fmt 4703 Sfmt 4725 E:\FR\FM\07SEN1.SGM 07SEN1 EN07SE07.044</GPH> mstockstill on PROD1PC66 with NOTICES 51456 VerDate Aug<31>2005 18:34 Sep 06, 2007 Jkt 211001 PO 00000 Frm 00054 Fmt 4703 Sfmt 4703 E:\FR\FM\07SEN1.SGM 07SEN1 51457 EN07SE07.045</GPH> mstockstill on PROD1PC66 with NOTICES Federal Register / Vol. 72, No. 173 / Friday, September 7, 2007 / Notices 51458 Federal Register / Vol. 72, No. 173 / Friday, September 7, 2007 / Notices [FR Doc. 07–4404 Filed 9–6–07; 8:45 am] BILLING CODE 4160–01–C DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. 2003N–0528] ‘‘Guidance for Industry: Manufacturing Biological Intermediates and Biological Drug Substances Using SporeForming Microorganisms’’; Availability AGENCY: Food and Drug Administration, HHS. ACTION: Notice. SUMMARY: The Food and Drug Administration (FDA) is announcing the availability of a document entitled ‘‘Guidance for Industry: Manufacturing Biological Intermediates and Biological Drug Substances Using Spore-Forming Microorganisms’’ dated September 2007. The guidance document is intended to provide guidance to manufacturers using spore-forming microorganisms in the production of certain biological products. The guidance document provides recommendations to industry in response to changes made to the requirements for spore-forming microorganisms to allow greater flexibility in manufacturing. The guidance announced in this notice finalizes the draft guidance entitled ‘‘Guidance for Industry: Manufacturing Biological Drug Substances, Intermediates, or Products Using SporeForming Microorganisms’’ dated February 2005. DATES: Submit written or electronic comments on agency guidances at any time. Submit written requests for single copies of the guidance to the Office of Communication, Training and Manufacturers Assistance (HFM–40), Center for Biologics Evaluation and Research (CBER), Food and Drug Administration, 1401 Rockville Pike, suite 200N, Rockville, MD 20852–1448. Send one self-addressed adhesive label to assist the office in processing your requests. The guidance may also be obtained by mail by calling CBER at 1– 800–835–4709 or 301–827–1800. See the SUPPLEMENTARY INFORMATION section for electronic access to the guidance document. Submit written comments on the guidance to the Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Submit mstockstill on PROD1PC66 with NOTICES ADDRESSES: VerDate Aug<31>2005 18:34 Sep 06, 2007 Jkt 211001 electronic comments to either https:// www.fda.gov/dockets.ecomments or https://www.regulations.gov. FOR FURTHER INFORMATION CONTACT: Valerie A. Butler, Center for Biologics Evaluation and Research (HFM–17), Food and Drug Administration, 1401 Rockville Pike, suite 200N, Rockville, MD 20852–1448, 301–827–6210. SUPPLEMENTARY INFORMATION: I. Background FDA is announcing the availability of a document entitled ‘‘Guidance for Industry: Manufacturing Biological Intermediates and Biological Drug Substances Using Spore-Forming Microorganisms’’ dated September 2007. The document provides guidance to manufacturers using spore-forming microorganisms in the production of certain biological products. The guidance document provides recommendations to industry in response to changes made to the requirements for spore-forming microorganisms to allow greater flexibility in manufacturing. In the Federal Register of December 30, 2003, FDA published the direct final rule entitled ‘‘Revision of the Requirements for Spore-Forming Microorganisms’’ (68 FR 75116) and the accompanying proposed rule entitled ‘‘Revision of the Requirements for Spore-Forming Microorganisms; Companion to Direct Final Rule’’ (68 FR 75179) to modify the regulatory requirements for the manufacturing of biological products with spore-formers to allow greater manufacturing flexibility. The modifications were intended to provide alternatives to the then-existing requirements for separate, dedicated facilities and equipment for work with spore-forming microorganisms. In the Federal Register of May 14, 2004 (69 FR 26768), FDA published the ‘‘Revision of the Requirements for Spore-Forming Microorganisms; Confirmation of Effective Date’’ confirming the effective date of June 1, 2004, for the direct final rule. In the Federal Register of February 24, 2005 (70 FR 9084), FDA announced the availability of the draft guidance dated February 2005. FDA received a few comments on the draft guidance, and those comments were considered as the guidance was finalized. In addition, editorial changes were made to improve clarity. The guidance announced in this notice finalizes the draft guidance dated February 2005. The guidance is being issued consistent with FDA’s good guidance practices regulation (21 CFR 10.115). PO 00000 Frm 00055 Fmt 4703 Sfmt 4703 The guidance represents the FDA’s current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. An alternative approach may be used if such approach satisfies the requirements of the applicable statutes and regulations. II. Comments Interested persons may submit to the Division of Dockets Management (see ADDRESSES) written or electronic comments regarding this guidance. Submit a single copy of electronic comments or two paper copies of any mailed comments, except that individuals may submit one paper copy. Comments are to be identified with the docket number found in brackets in the heading of this document. A copy of the guidance and received comments may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday. III. Electronic Access Persons with access to the Internet may obtain the guidance at either https:// www.fda.gov/cber/guidelines.htm or https://www.fda.gov/ohrms/dockets/ default.htm. Dated: August 31, 2007. Jeffrey Shuren, Assistant Commissioner for Policy. [FR Doc. E7–17709 Filed 9–6–07; 8:45 am] BILLING CODE 4160–01–S DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Center on Minority Health and Health Disparities; Notice of Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the National Advisory Council on Minority Health and Health Disparities. The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial E:\FR\FM\07SEN1.SGM 07SEN1

Agencies

[Federal Register Volume 72, Number 173 (Friday, September 7, 2007)]
[Notices]
[Pages 51449-51458]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 07-4404]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[FDA 225-07-8405]


Memorandum of Understanding Between the Food and Drug 
Administration and the University System of Maryland

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is providing notice of 
a memorandum of understanding (MOU) between FDA and the University 
System of Maryland to establish terms of collaboration to support 
shared interests that can proceed through a variety of programs 
including collaborative research, public outreach, cooperative 
international initiatives, interdisciplinary training, and exchange of 
scientists and staff through sabbaticals, postdoctoral fellowships, and 
student internships.

DATES: The agreement became effective July 12, 2007.

FOR FURTHER INFORMATION CONTACT: Mary I. Poos, Office of External 
Relations (HF-10), Food and Drug Administration, 5600 Fishers Lane, 
Rockville, MD 20857, 301-827-2825.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 20.108(c), which 
states that all written agreements and MOUs between FDA and others 
shall be published in the Federal Register, the agency is publishing 
notice of this MOU.

    Dated: August 29, 2007.
Jeffrey Shuren,
Assistant Commissioner for Policy.
BILLING CODE 4160-01-S

[[Page 51450]]

[GRAPHIC] [TIFF OMITTED] TN07SE07.038


[[Page 51451]]


[GRAPHIC] [TIFF OMITTED] TN07SE07.039


[[Page 51452]]


[GRAPHIC] [TIFF OMITTED] TN07SE07.040


[[Page 51453]]


[GRAPHIC] [TIFF OMITTED] TN07SE07.041


[[Page 51454]]


[GRAPHIC] [TIFF OMITTED] TN07SE07.042


[[Page 51455]]


[GRAPHIC] [TIFF OMITTED] TN07SE07.043


[[Page 51456]]


[GRAPHIC] [TIFF OMITTED] TN07SE07.044


[[Page 51457]]


[GRAPHIC] [TIFF OMITTED] TN07SE07.045


[[Page 51458]]


[FR Doc. 07-4404 Filed 9-6-07; 8:45 am]
BILLING CODE 4160-01-C

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.